With gratitude and satisfaction we present to you Boehringer Ingelheim’s positive results for 2017 in this Annual Report. This report is the proof that we reached more patients – both human and animal – and that with our medicines we made a positive contribution to their disease progression and thereby to their health.
Over the past few years, the structure and positioning of our company have undergone fundamental change. And even if the work is not quite finished, we have already successfully completed the fundamental tasks.
Boehringer Ingelheim’s primary objective is and remains to maintain our independence as a family-owned company, at the same time helping people and animals with innovative medicines. We are convinced that the dedication and commitment of our staff is of great value over and above economic success. In 2017, we once again clearly demonstrated where we come from and who we are. With the global “Our FOCUS” initiative, we described our path towards innovation and growth in the future.
In times of change and upheaval in particular, this gives all our employees clear, joint orientation and motivation. We would like to expressly thank each and every one of them for successfully stepping up to the challenges of the past year and for all their energy and commitment in working to achieve our company goals.
Chairman of the Shareholders’ Committee